Vyriad develops targeted viral genetic medicines and oncolytic therapies. Its BCMA-directed in vivo CAR-T candidate VV169 uses a retargeted lentiviral vector to engineer T cells inside the body. On September 10, 2026, the company announced that its Phase 1 study in relapsed/refractory multiple myeloma was open for enrollment at Mayo Clinic following FDA IND clearance. Patient dosing and clinical benefit were not established in that announcement.
2025-12-23 · Series B — final tranche · US$25 million final tranche (US$85 million total Series B) ↗
Final tranche only; US$85 million is this round total, not all-time cumulative funding.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Vyriad develops targeted viral genetic medicines and oncolytic therapies. Its BCMA-directed in vivo CAR-T candidate VV169 uses a retargeted lentiviral vector to engineer T cells inside the body. On September 10, 2026, the company announced that its Phase 1 study in relapsed/refractory multiple myeloma was open for enrollment at Mayo Clinic following FDA IND clearance. Patient dosing and clinical benefit were not established in that announcement.
Program / service
Target / indication
Representative stage
Evidence & scope
VV169
BCMA · Relapsed/refractory multiple myeloma
Phase 1
Open enrollment does not establish dosing or efficacy.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.
Azalea reported SITC preclinical findings for its dual-vector in vivo CAR-T platform, combining targeted CRISPR-Cas9 delivery with AAV-mediated CAR insertion at the TRAC locus. The company described leukemia clearance and protection after tumor rechallenge in selected mouse groups, plus dual-antigen and armored designs. These are animal findings, not evidence of efficacy or safety in patients.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
